Revolution Medicines expects full year 2023 GAAP net loss to be between $335 and $365M, which includes estimated non-cash stock-based compensation expense of $40M and $50M.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on RVMD:
- Revolution Medicines Blasts Up after Earnings
- Revolution Medicines Reports Fourth Quarter and Full Year 2022 Financial Results and Update on Corporate Progress
- Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2022 After Market Close on February 27, 2023
- Revolution Medicines to Participate in Upcoming Investor Conferences